Polpharma Biologics will retain full responsibility for developing and manufacturing the biosimilar candidate.

Apertura has entered a cooperative research and development agreement (CRADA) with various NIH institutes for a gene therapy ...

Hyponatraemia is the most common electrolyte abnormality among hospital inpatients, with clinical manifestations ranging from ...

Halozyme Therapeutics trades at $78.57 and has moved in lockstep with the market. Its shares have returned 8.5% over the last ...

Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances T ...

A four-month-old baby died at a Nottingham hospital after "omissions of care" prompted concerns from her bereaved parents.

Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today ...

Teva secures exclusive global rights to commercialize Polpharma Biologics' biosimilar candidate to Ocrevus (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances T ...

Denali co-founder and CEO Ryan Watts, Ph.D., to deliver opening plenary address at 2026 AAIC in London on July 12, 2026Presentation will highlight recent scientific advances and future opportunities ...

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its CEO, Rob Fried, will ...

Here's What Other Cities Can Learn From Its Blueprint FFor most kids, childhood is measured by familiar defining events: pool ...

Gary Black Says Tesla's Valuation Is So 'Stretched' That Most Institutional Investors Won't Touch the Stock— and FSD Isn't Helping Paramount's $110 Billion Warner Bros. Deal Keeps Getting Delayed ...